Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2005

View Archived Issues

Second closing of Cellerant Therapeutics' Series B financing

NAP and ADNF-9 exert neuroprotective effects via PARP-1 activation and polyADP-ribosylation

IFN-alpha-XL shows promise in the management of chronic hepatitis C

First data on the antitumor efficacy of artesunate in metastatic uveal melanoma

Cubist submits Cubicin sNDA filing, requests priority review

Glenmark seeks clearance for phase I trials of DPP-IV inhibitor GRC-8200

International Medical Innovations changes name to PreMD

Revised reporting date for phase III study of Corlux

Corcept closes enrollment in Corlux study in Alzheimer's patients

Low dose oral interferon alpha studied for bone marrow proliferative disorders

ADX-10059 enters phase I studies for anxiety disorders and migraine

VT-111 begins phase II trial for acute coronary syndromes

Actilon begins phase Ib study for chronic HCV

AT-1001 enters phase I testing for celiac disease

Tissue distribution of SVT-40776 indicates a good safety profile

Pentacel BLA accepted for filing

UR-1505 modulates T cell proliferation and cytokine production

New data presented on GSK-3 dual inhibitor that demonstrates bone formation

Lck inhibition prevents acute rejection of heart transplants

Regeneron updates progress of key programs

Exatecan mesilate investigated in metastatic gastric cancer

Approvable letter for iPlex

Positive opinions in Europe for Combigan

Studies reveal temsirolimus activity in different cancers

Stiefel licenses albaconazole from Uriach

Recent patents report novel treatments for obesity

DOV-216303 shows promise in the management of major depression

Phase I data on arsenic trioxide plus dacarbazine in metastatic melanoma

Canvaxin improves survival of patients with high-risk melanoma

New thrombin inhibitors claimed in AstraZeneca patent

BAY-43-9006 shows antitumor activity in metastatic melanoma

Novel agents for diabetes and related complications reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...